ICGex
Cabel L. et al.
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-conceptstudy.
Ann Oncol. (2017) Aug. 28(8):1996-2001.
doi: 10.1093/annonc/mdx212
Pincez T. et al.
Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pediatr Blood Cancer (2017) Jun. 64(6).
doi: 10.1002/pbc.26365
Le Tourneau C. et al.
The SHIVA01 trial: what have we learned?
Pharmacogenomics (2017) Jun. 18(9):831-834.
doi: 10.2217/pgs-2017-0062
Richer W. et al.
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.
Oncotarget (2017) May. 8(21):34245-34257.
doi: 10.18632/oncotarget.15939
Euceda LR. et al.
Metabolic response to Everolimus in patient-derived triple-negative breast cancer xenografts.
J Proteome Res. (2017) May. 16(5):1868-1879.
doi: 10.1021/acs.jproteome.6b00918
Portoso M. et al.
PRC2 is dispensable for HOTAIR-mediated transcriptional repression.
EMBO J. (2017) Apr. 36(8):981-994.
doi: 10.15252/embj.201695335
Perez-Rico YA. et al.
Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomes.
Genome Res. (2017) Feb. 27(2):259-268.
doi: 10.1101/gr.203679.115
Greenberg MV. et al.
Transient transcription in the early embryo sets an epigenetic state that programs postnatal growth.
Nat Genet. (2017) Jan. 49(1):110-118.
doi: 10.1038/ng.3718
Chauvin C. et al.
High-throughput drug screening identifies Pazopanib and Clofilium Tosylate as promising treatments for Malignant Rhabdoid Tumors.
Cell Rep. (2017) Nov. 21(7):1737-1745.
doi: 10.1016/j.celrep.2017.10.076
Plouhinec JL. et al.
A molecular atlas of the developing ectoderm defines neural, neural crest, placode, and nonneural progenitor identity in vertebrates.
PLoS Biol. (2017) Oct. 15(10):e2004045.
doi: 10.1371/journal.pbio.2004045